Plus Therapeutics, Inc. (PSTV)
Largest Insider Buys in Sector
PSTV Stock Price History Chart
PSTV Stock Performance
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori …
Insider Activity of Plus Therapeutics, Inc.
Over the last 12 months, insiders at Plus Therapeutics, Inc. have bought $190,808 and sold $4,053 worth of Plus Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Plus Therapeutics, Inc. have bought $89,709 and sold $2,262 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Petersen Greg (director) — $125,626. Hawkins Richard J (director) — $73,524. Lenk Robert P (director) — $47,700.
The last purchase of 4,000 shares for transaction amount of $5,996 was made by Hawkins Richard J (director) on 2024‑09‑13.
List of Insider Buy and Sell Transactions, Plus Therapeutics, Inc.
| 2024-09-13 | director | 4,000 0.0687% | $1.50 | $5,996 | -5.07% | |||
| 2024-09-12 | director | 6,285 0.1009% | $1.35 | $8,512 | -1.40% | |||
| 2024-09-11 | director | 12,500 0.2271% | $1.35 | $16,875 | 0.00% | |||
| 2024-09-11 | director | 5,000 0.0899% | $1.34 | $6,681 | 0.00% | |||
| 2024-09-10 | Chief Executive Officer | 8,000 0.1324% | $1.23 | $9,839 | +11.90% | |||
| 2024-09-10 | Chief Financial Officer | 4,098 0.0701% | $1.27 | $5,204 | +11.90% | |||
| 2024-05-08 | director | 12,255 0.2576% | $2.04 | $25,000 | -29.52% | |||
| 2024-05-08 | director | 4,167 0.0876% | $2.04 | $8,501 | -29.52% | |||
| 2024-05-08 | director | 9,804 0.206% | $2.04 | $20,000 | -29.52% | |||
| 2024-05-08 | Chief Executive Officer | 12,255 0.2576% | $2.04 | $25,000 | -29.52% | |||
| 2024-05-08 | Chief Financial Officer | 4,902 0.103% | $2.04 | $10,000 | -29.52% | |||
| 2024-05-08 | director | 4,902 0.103% | $2.04 | $10,000 | -29.52% | |||
| 2023-11-20 | Sale | Chief Executive Officer | 2,068 0.0487% | $1.96 | $4,053 | +2.22% | ||
| 2023-11-16 | director | 1,000 0.02% | $1.95 | $1,950 | -15.98% | |||
| 2023-11-15 | director | 1,000 0.0206% | $1.77 | $1,770 | -1.60% | |||
| 2023-11-13 | director | 4,000 0.086% | $1.43 | $5,720 | +25.17% | |||
| 2023-11-10 | director | 2,000 0.0452% | $1.45 | $2,900 | +30.96% | |||
| 2023-11-09 | director | 4,199 0.0971% | $1.59 | $6,676 | +23.32% | |||
| 2023-11-08 | director | 5,000 0.1147% | $1.65 | $8,250 | +15.72% | |||
| 2023-11-07 | director | 6,000 0.1303% | $1.64 | $9,840 | +11.52% |
Insider Historical Profitability
| Petersen Greg | director | 48921 0.8297% | $1.41 | 7 | 0 | <0.0001% |
| Lenk Robert P | director | 29327 0.4974% | $1.41 | 11 | 1 | <0.0001% |
| Clowes Howard | director | 26497 0.4494% | $1.41 | 7 | 0 | <0.0001% |
| HEDRICK MARC H | Chief Executive Officer | 20425 0.3464% | $1.41 | 28 | 2 | <0.0001% |
| Hawkins Richard J | director | 15188 0.2576% | $1.41 | 4 | 0 | <0.0001% |